PMID- 38449010
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240308
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 45
IP  - 2
DP  - 2024 Mar 1
TI  - Total IgE as a biomarker of omalizumab response in chronic spontaneous urticaria: 
      A meta-analysis.
PG  - 97-99
LID - 10.2500/aap.2024.45.230092 [doi]
AB  - Background: Omalizumab is approved for the treatment of chronic spontaneous 
      urticaria (CSU) that is refractory to antihistamines. Total immunoglobulin E 
      (IgE) levels have emerged as a possible biomarker to predict response to 
      omalizumab. However, the existing literature is heterogenous, with conflicting 
      conclusions with regard to the role of total IgE levels. Objective: We sought to 
      clarify the role of evaluating total IgE levels in patients with CSU by 
      performing a meta-analysis on the existing literature to determine if meaningful 
      changes exist between responders and nonresponders to omalizumab. Methods: A 
      total of 68 unique citations were returned and screened by two independent 
      reviewers. Editorials, reviews, and case reports were excluded, and a total of 33 
      original articles were identified and underwent secondary evaluation. Studies 
      that present mean +/- standard deviation total IgE levels and/or 95% confidence 
      intervals (CI) were included, whereas studies with < 25 subjects were excluded. 
      Three studies ultimately met these criteria. Results: We found a mean difference 
      in total IgE levels between those who responded to omalizumab versus those 
      without a response of 49.76 (95% CI, 7.13-92.38; p = 0.02), which demonstrated 
      higher mean IgE values in responders compared with nonresponders. Conclusion: 
      This study presents additional evidence that supports evaluation of total IgE 
      levels as it pertains to response to omalizumab therapy in CSU. When considering 
      the current evidence, it seems reasonable to consider the baseline total IgE 
      level as a biomarker to predict the treatment response to omalizumab. Based on 
      the existing literature, we cannot conclude at what threshold nonresponse is more 
      likely to occur.
FAU - Keller, Levi
AU  - Keller L
AD  - From the Division of Allergy and Clinical Immunology, Department of Medicine, 
      University of Colorado Denver School of Medicine, Aurora, Colorado.
FAU - Perera, Ekta K
AU  - Perera EK
AD  - Division of Pulmonary and Sleep Medicine, Department of Internal Medicine, 
      University of Texas Health Science Center at Houston, Houston, Texas.
FAU - Bindon, Brittany
AU  - Bindon B
AD  - Division of Pediatric Allergy and Immunology, Department of Pediatrics, 
      University of Chicago Medicine, Chicago, Illinois, and.
FAU - Khatiwada, Aastha
AU  - Khatiwada A
AD  - Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, 
      Colorado.
FAU - Stitt, Jenny M
AU  - Stitt JM
AD  - From the Division of Allergy and Clinical Immunology, Department of Medicine, 
      University of Colorado Denver School of Medicine, Aurora, Colorado.
FAU - Dreskin, Stephen C
AU  - Dreskin SC
AD  - From the Division of Allergy and Clinical Immunology, Department of Medicine, 
      University of Colorado Denver School of Medicine, Aurora, Colorado.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Biomarkers)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - *Omalizumab/therapeutic use
MH  - *Chronic Urticaria/drug therapy
MH  - Biomarkers
MH  - Immunologic Tests
MH  - Immunoglobulin E
EDAT- 2024/03/07 00:42
MHDA- 2024/03/08 06:43
CRDT- 2024/03/06 23:48
PHST- 2024/03/08 06:43 [medline]
PHST- 2024/03/07 00:42 [pubmed]
PHST- 2024/03/06 23:48 [entrez]
AID - 10.2500/aap.2024.45.230092 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2024 Mar 1;45(2):97-99. doi: 10.2500/aap.2024.45.230092.